Literature DB >> 10229110

Contrasting roles for nitric oxide and peroxynitrite in the peroxidation of myelin lipids.

R C van der Veen1, L J Roberts.   

Abstract

Peroxynitrite is formed by the reaction of nitric oxide (NO) and superoxide. Since widespread peroxynitrite activity was observed during experimental allergic encephalomyelitis (EAE), the effect of this strong lipid-peroxidizing agent on myelin integrity was examined. Incubation of myelin suspensions with the peroxynitrite donor 3-morpholinosydnonimine (SIN-1) resulted in the formation of the lipid peroxidation product, malondialdehyde (MDA). MDA formation was inhibited in the presence of butylated hydroxytoluene, which interrupts the progression of the lipid peroxidation chain reaction. Superoxide dismutase inhibited the effect of SIN-1, which indicates a role for superoxide, and contradicts a role for its dismutation product, hydrogen peroxide. The latter was confirmed by the failure of the catalase to inhibit MDA formation. Neither NO nor superoxide alone induced significant MDA formation in myelin, indicating that peroxynitrite formation is required for myelin-lipid peroxidation. Interestingly, NO actually inhibited lipid peroxidation in myelin, as demonstrated using simple NO donors. On the other hand, the simultaneous production of superoxide, as achieved with the NO-donor SIN-1, negated the inhibitory effect of NO. Finally, the production of isoprostanes, novel products generated during lipid peroxidation, was examined. Peroxynitrite-induced peroxidation of myelin resulted in isoprostane formation. Furthermore, increased levels of F2-isoprostanes and neuroprostanes were observed in spinal cords of mice during early progressive stages of autoimmune encephalomyelitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229110     DOI: 10.1016/s0165-5728(98)00239-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

1.  Aminoguanidine and N-acetyl-cysteine supress oxidative and nitrosative stress in EAE rat brains.

Authors:  Srdjan Ljubisavljevic; Ivana Stojanovic; Dusica Pavlovic; Dusan Sokolovic; Ivana Stevanovic
Journal:  Redox Rep       Date:  2011       Impact factor: 4.412

Review 2.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

Review 3.  Lame ducks or fierce creatures? The role of oligodendrocytes in multiple sclerosis.

Authors:  T Zeis; N Schaeren-Wiemers
Journal:  J Mol Neurosci       Date:  2008-02-16       Impact factor: 3.444

4.  Decreased glycolytic and tricarboxylic acid cycle intermediates coincide with peripheral nervous system oxidative stress in a murine model of type 2 diabetes.

Authors:  Lucy M Hinder; Anuradha Vivekanandan-Giri; Lisa L McLean; Subramaniam Pennathur; Eva L Feldman
Journal:  J Endocrinol       Date:  2013-01-02       Impact factor: 4.286

5.  Low serum urate levels are associated to female gender in multiple sclerosis patients.

Authors:  Stefano Zoccolella; Carla Tortorella; Pietro Iaffaldano; Vita Direnzo; Mariangela D'Onghia; Elena Luciannatelli; Damiano Paolicelli; Paolo Livrea; Maria Trojano
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

6.  Redox signaling pathways involved in neuronal ischemic preconditioning.

Authors:  John W Thompson; Srinivasan V Narayanan; Miguel A Perez-Pinzon
Journal:  Curr Neuropharmacol       Date:  2012-12       Impact factor: 7.363

7.  Oxidative and Nitrosative Stress and Immune-Inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS).

Authors:  Gerwyn Morris; Michael Maes
Journal:  Curr Neuropharmacol       Date:  2014-03       Impact factor: 7.363

8.  Neuroprotective effect of nitric oxide donor isosorbide-dinitrate against oxidative stress induced by ethidium bromide in rat brain.

Authors:  Omar M E Abdel-Salam; Yasser Ashry Khadrawy; Nadia A Mohammed
Journal:  EXCLI J       Date:  2012-03-29       Impact factor: 4.068

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.